S2 Ep13: Your Beta Program Is Lying to You.

Transcript

In this episode, Matt Wilkinson and Jasmine debate the structural design of beta programs in RUO life sciences. Starting from a brief audit framework and moving through failure mode testing, negative finding attribution, and the commercial politics of rigorous program design, the conversation builds a practical case for treating the beta as a diagnostic instrument rather than a validation exercise.

Opening and context

Speaker: Matt Wilkinson

Hi Jasmine, how you doing today? I'm good, thank you. Hey, nice mug.

Speaker: Jasmine

Hey, hey, how are you? Thank you. It's ages old from Corning.

Speaker: Matt Wilkinson

And so is it made with glass?

Speaker: Jasmine

Ha, good one. No, no, it's a ceramic mug. Takes me back to my days in the lab.

Speaker: Matt Wilkinson

Nice. Speaking of which, today's episode is all about beta programs and taking products to the lab. You wrote a really interesting blog with quite a provocative title saying your beta program is lying to you. So I'm looking forward to diving into where the lies are coming from.

The comfort-driven beta and the brief audit

Speaker: Matt Wilkinson

I want our listeners to think back to the last beta program they ran. The sites completed the study, a KOL sent a positive note. Nobody filed a reproducibility complaint. You called it validation and moved to launch. Then, three months after launch, your field application scientist hit an edge case none of your beta sites ever flagged. The problem could have been found out, but the program wasn't designed to find it.

Today, we're going to be debating a framework outlined for designing beta programs and argue that the brief, the environment, and the debrief are all controllable by the product manager. And they're all levers that are easily within the realms of making sure that essentially the experiment of the beta program is set up exactly the way to find out these edge cases. I'm looking forward to diving into this.

Speaker: Jasmine

Move for it.

Speaker: Matt Wilkinson

So you say a brief with a three-to-one ratio of strengths to stress tests asked as a kind of testimonial request. And I think this sort of hints at most organisations trying to find out the value that the new product is going to deliver rather than trying to find out the problems that people may encounter with it. Most beta sites are recruited through existing relationships where you already have a good relationship, you already have credibility, and the product manager has a limited authority to sort of demand critical evaluation. Now is the brief audit testing product management authority the organisation has not actually granted?

Speaker: Jasmine

I'd offer that the brief is within the product manager's authority, regardless of where they fit in the org chart. A site briefed explicitly to stress test produces categorically different engagement than a site briefed to evaluate general performance.

That doesn't require formal authority. It requires a product manager who decides that diagnostic framing is their job.

The three-to-one audit isn't a performance standard. It's a signal. A brief with 12 sentences describing product strengths and three sentences asking sites to find problems is telling you something about what the product manager believes the beta is for. If the brief reads as a confidence document, the program will run as a confidence program. You're basically setting up those expectations. The sites most valuable to your commercial claims are scientific collaborators, not QC subcontractors. When they understand that candid negative findings will shape the product, they engage differently, and that shift starts with the brief.

KOL relationships versus diagnostic rigour

Speaker: Matt Wilkinson

Yeah, it's interesting, isn't it? Because the relationship really matters, maybe more than the brief framing in many ways. A product manager who pushes too hard on stress test language with a valued collaborator risks damaging that relationship and maybe even reputation, surely. Do we not need to be diplomatically framing areas of uncertainty as conditions we'd like you to stress test, quite a bit different from genuinely inviting negative findings? We know that KOLs who go on stage talking about products have a more positive perception of those products. They need their internal narrative to align with what they're saying. So do we not risk potentially biasing their opinions of the product in the future by asking them for that honest exploration of the edge cases and where things could go wrong?

Speaker: Jasmine

The distinction between diplomatic framing on the one hand and genuine invitation is exactly what the brief quality test is measuring.

If your KOL consistently produces soft positive signal regardless of how you frame the brief, that's information about what kind of collaborator they are. But a KOL reference built on a comfort-driven program is a commercial liability, frankly. A KOL reference built on a program that stress tested hard conditions and confirmed performance anyway, that's a real, durable asset. The brief framing isn't the only variable, but it's the only one that the product manager controls before the program runs. Optimising for relationship comfort at the briefing stage is a choice to find out about your product problems at launch instead. You're basically kicking the can down the road. The relationship risk argument assumes the KOL's credibility is served better by soft validation than by rigorous co-authorship. For serious scientific collaborators, that assumption is usually wrong.

Structured failure mode testing and the limits of internal validation

Speaker: Matt Wilkinson

That's fair. So you advocate building structured failure mode arms into the program, identifying maybe three conditions that are most likely to produce variable results and asking people to test them explicitly. But if you already know which conditions are likely to produce variable results, aren't those conditions the R and D team should already have addressed before the beta? What does structured failure mode testing really look like when you're testing that in the field? What does it add that internal validation doesn't cover?

Speaker: Jasmine

This is a really important point that I think a lot of folks miss.

Internal validation and beta serve very different evidentiary functions. Internal validation tests whether the product works under controlled conditions. Beta tests whether it works under conditions you can't replicate in R and D. An operator skill range, sample type diversity, instrument configuration variability across customer labs. The conditions most likely to produce variable results at beta are not typically the conditions that R and D missed. They're the conditions R and D never tested because replicating a core facility director running complex tissue lysates with a less experienced operator just isn't possible in a controlled R and D environment.

Structured failure mode testing is not a remediation of internal validation gaps. It's a stress test for the transition from controlled to field conditions. For example, a QPCR reagent that performs well on purified inputs and fails under degraded RNA inputs is not a product with an R and D failure. It's a product with an unlabelled use condition. Finding that at beta earns you a specific claim boundary, but missing it earns you a field quality crisis that I can guarantee your FASs don't want to have to deal with.

Commercial pressure, schedule risk, and the brand protection case

Speaker: Matt Wilkinson

I guess the question here is, launch teams fund beta programs to generate claims evidence and to generate it on schedule. A product manager who designs an additional beta arm to test degraded RNA inputs, for example, is adding time and site coordination to a program that commercial leadership has already scoped as tightly as possible.

The implicit assumption is the failure mode testing is that the problem found is fixable before launch. But if the failure mode on surface is a formulation issue that requires a three-month remediation cycle, has the product manager protected the launch, or have they just delayed it? Commercial teams remember delays. They don't always remember the justification that came with them. So I completely agree that you don't want to put KOLs in a position where they're saying something like this is the best thing since sliced bread and all of a sudden somebody says, hey, but you can't toast it. But does this -- is this one of those things where we have to be careful about the culture and the organisation?

Speaker: Jasmine

The formulation issue doesn't disappear if the beta doesn't find it. It surfaces in customers' hands three to six months post-launch.

You end up with an accumulation of field reports until the pattern is visible enough for action. At that stage, remediation includes FAS's time, customer relationship repair, and credibility damage to every claim made on data that didn't hold.

The three months fixed before launch likely costs a fraction of that. The framing for the launch team is not: we added a beta arm. It's: we identified a failure mode, confirmed it occurs under specific conditions, and can now make a claim boundary that's commercially defensible instead of vulnerable.

That's a launch risk removed, not a delay added. Yeah, the political challenge is real. I acknowledge that. The response to it is in the framing, not in avoiding program rigour.

Speaker: Matt Wilkinson

It sounds like it's almost a brand protection play as much as anything else. Really interesting to see that a beta test could actually be a brand protection play. But you also highlight that when negative findings come back, the instinct can be to attribute them to operator error or non-representative samples, and that product managers should assume a product issue until proven otherwise.

But in life sciences, distinguishing a genuine product failure from a site-specific operator problem is hard. To assume product issue first -- is that the right default, or does it create its own bias? Sending teams on remediation cycles for problems that were not actually the product's fault.

Attribution defaults and asymmetric risk

Speaker: Jasmine

The default isn't assume product issue regardless. It's: before reaching for any explanation, ask whether this finding would reoccur in a customer's hands. If the answer is possibly yes, treat it as a product issue until the evidence says otherwise. That's a different default from assume operator error, and it's a different default from assume product issue regardless. The reason to set the default toward product investigation rather than operator attribution is asymmetrical risk. If you investigate a finding and conclude it was genuinely operator-specific, you've spent time and confirmed the product is clean. If you attribute a finding to operator error and you're wrong, you've launched with a known failure mode you chose not to investigate. Those are not equivalent errors. The first costs you a week of investigation. The second potentially costs you a field quality crisis. The blog is also not asking product managers to ignore context. A finding from a site that demonstrably ran the protocol incorrectly is different from a finding that appeared across two sites with no obvious procedural deviation. The framework asks product managers to be honest about what category their finding falls into before the attribution instinct kicks in.

Speaker: Matt Wilkinson

One question though. Isn't the possibly yes test harder to apply than it sounds? Isn't operator variability genuinely high in many places? We know that pipetting variability, for example, can be massive. And the pipette can be perfectly calibrated and it's the operator that's off. So I just wonder: how do you accommodate that sort of variability? Or is that actually precisely what we're testing?

If a user can't reliably get to the right answer, then something needs to be either explained or taught. There needs to be something in the product or around the product that gets you to a consistent response. I'm looking at this as potentially the framework is right, that comfort-driven attribution is a real problem. But how do we get past that? How do we avoid over-correcting and moving into spaces where we're really starting to move into education around basic operator usage of tools that you're not actually selling?

Speaker: Jasmine

In the blog, I talk about a Western blot example, which is exactly the kind of finding the framework is designed to surface and force a decision on. A finding that would recur in 15% of customers' hands is a claim boundary problem, not an operator training problem. Those are commercially different. A claim that implies broad applicability and fails for 15% of users generates field quality reports. A claim that specifies the conditions under which performance holds generates a defensible product that an FAS can support. So the corrective and protective action -- the CAPA concern -- is a real organisational constraint and worth flagging to product managers before the data runs.

The answer isn't to lower the attribution threshold. It's to agree before the program starts what evidence standard triggers a formal remediation versus a protocol clarification versus a claims adjustment. That agreement belongs in the program design -- just like any good experiment. You've got to have the goal set out at the beginning. It's not in the debrief interpretation where the pressure to close the finding quickly is the highest. The instinct to attribute negative findings to operator error isn't a neutral heuristic. It's specifically the instinct that comfort-driven programs are built around. The framework challenges it because the cost of getting that attribution wrong is almost always borne by the customer, and that is absolutely the last thing you want to have happen.

Resolution and closing

Speaker: Jasmine

Here is where I land. The brief audit, the conditions gap test, and the structured debrief are all within the product manager's authority and remit. None of them require organisational transformation. Your challenges were about the relationship costs and the political framing, and those are real. But they're arguments for going in with your eyes wide open, not arguments for designing a more comfortable program.

Speaker: Matt Wilkinson

I agree that the framework's logic holds. It's true that the organisational reality around KOL relationships and leadership reception of bad news is hard. Product managers who design a rigorous program are trying to manage brand equity in the long term rather than a short-term timeline. So it definitely makes sense.

Speaker: Jasmine

Yeah, as always great conversation, Matt. Cheers.

Speaker: Matt Wilkinson

Thank you so much. Look forward to speaking on the next one.

Speaker: Jasmine

Sounds good. Bye for now.

Q&A

How do I know if my current beta brief is designed for confidence rather than diagnosis?

Count the sentences. Lay out your brief and tally how many describe product strengths versus how many explicitly ask sites to find conditions where performance breaks down. If the ratio is three-to-one or worse in favour of strengths, you have a confidence document. The fix is straightforward: add three to five named failure conditions you want sites to test, framed as specific questions rather than open invitations to evaluate general performance.

My launch timeline is already tight. How do I make the case for adding a failure mode arm to the beta without looking like I am slowing things down?

Reframe the ask entirely. You are not adding a beta arm -- you are identifying the specific conditions under which your existing claims become commercially indefensible. Present it to the launch team as a claim boundary exercise: here are three conditions that, if untested, leave us exposed to field quality reports six months post-launch. Here is the evidence standard that would either close each condition or trigger a defined response. That is a risk removal conversation, not a delay conversation.

When a negative finding comes back, what is the first question I should ask before reaching for an explanation?

Ask: would this finding reoccur in 15% or more of customer hands using standard lab practice? If the honest answer is possibly yes, treat it as a product issue until the evidence says otherwise. Do not start with operator attribution. Start with recurrence probability. That single shift in default question changes the investigation that follows and, more importantly, changes the launch decision you make if the investigation runs short on time.

How do I get a KOL to engage with stress testing without damaging the relationship or biasing their future advocacy?

Position them as a co-author of the claim, not a QC contractor. The framing is: your candid findings under hard conditions are what make this reference commercially durable. A KOL whose endorsement is built on a comfort program is a liability if a field issue surfaces later. A KOL whose endorsement survived rigorous stress testing is a defensible asset. Serious scientific collaborators respond to that framing. If yours consistently produce soft positive signal regardless, that is information about fit, not a reason to soften the brief.

What should be agreed before the beta program starts rather than decided during the debrief?

Three things: the evidence standard that triggers a formal remediation versus a protocol clarification versus a claims adjustment; the named failure conditions you expect the program to surface; and the attribution criteria that distinguish a site-specific operator issue from a finding that would recur across customers. Agreeing these upfront removes the pressure that drives comfort-driven attribution during the debrief, when the incentive to close findings quickly is at its highest.